[go: up one dir, main page]

ECSP088613A - Moléculas de anticuerpo que tienen especificidad para la il-6 humana - Google Patents

Moléculas de anticuerpo que tienen especificidad para la il-6 humana

Info

Publication number
ECSP088613A
ECSP088613A EC2008008613A ECSP088613A ECSP088613A EC SP088613 A ECSP088613 A EC SP088613A EC 2008008613 A EC2008008613 A EC 2008008613A EC SP088613 A ECSP088613 A EC SP088613A EC SP088613 A ECSP088613 A EC SP088613A
Authority
EC
Ecuador
Prior art keywords
antibody molecules
specificity
human
producing
methods
Prior art date
Application number
EC2008008613A
Other languages
English (en)
Inventor
Andrew George Popplewell
Richard Evan Gelinas
Mitra Choudhury Singhal
Yi Zhang
Ralph Adams
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37714544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088613(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of ECSP088613A publication Critical patent/ECSP088613A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se relaciona con las moléculas de anticuerpo que tienen especificidad para determinantes antigénicos de la IL-6, los usos terapéuticos de las moléculas de anticuerpo y los métodos para producir dichas moléculas de anticuerpo.
EC2008008613A 2005-12-09 2008-07-07 Moléculas de anticuerpo que tienen especificidad para la il-6 humana ECSP088613A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74892605P 2005-12-09 2005-12-09

Publications (1)

Publication Number Publication Date
ECSP088613A true ECSP088613A (es) 2008-08-29

Family

ID=37714544

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008613A ECSP088613A (es) 2005-12-09 2008-07-07 Moléculas de anticuerpo que tienen especificidad para la il-6 humana

Country Status (28)

Country Link
US (5) US8075889B2 (es)
EP (3) EP1960430B1 (es)
JP (1) JP5183484B2 (es)
KR (2) KR101422523B1 (es)
CN (1) CN101356194B (es)
AR (1) AR057224A1 (es)
AU (1) AU2006323490B2 (es)
BR (1) BRPI0619595B8 (es)
CA (1) CA2632628C (es)
DK (1) DK1960430T3 (es)
EA (1) EA018044B1 (es)
EC (1) ECSP088613A (es)
ES (1) ES2525325T3 (es)
HK (1) HK1125113A1 (es)
HR (1) HRP20141214T1 (es)
IL (2) IL191600A (es)
MY (1) MY147217A (es)
NO (1) NO344847B1 (es)
NZ (1) NZ569234A (es)
PE (1) PE20070998A1 (es)
PL (1) PL1960430T3 (es)
PT (1) PT1960430E (es)
RS (1) RS53708B1 (es)
SI (1) SI1960430T1 (es)
TW (1) TWI390035B (es)
UA (1) UA96141C2 (es)
WO (1) WO2007066082A1 (es)
ZA (1) ZA200804594B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
SI1960430T1 (sl) * 2005-12-09 2015-01-30 Ucb Pharma, S.A. Molekule protiteles s specifiäśnostjo za äśloveĺ ki il-6
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
SI2182981T1 (sl) 2007-08-02 2013-05-31 Gilead Biologics, Inc. Postopki in sestavki za zdravljenje in diagnozo fibroze
ES2564635T3 (es) 2008-05-13 2016-03-28 Novimmune Sa Anticuerpos anti-IL-6/IL-6R y métodos de uso de los mismos
WO2010056948A2 (en) * 2008-11-13 2010-05-20 Femta Pharmaceuticals, Inc. Humanized anti-il-6 antibodies
WO2010065072A1 (en) 2008-11-25 2010-06-10 Alden Biopharmaceuticals, Inc. Antagonists of il-6 to raise albumin and/or lower crp
WO2010080769A2 (en) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
EP2467396A4 (en) * 2009-08-21 2012-12-26 Gilead Biologics Inc CATALYTIC DOMAINS FROM LYSYL OXIDASE AND LOXL2
RU2012110580A (ru) * 2009-08-21 2013-09-27 Джилид Байолоджикс, Инк. Способы скрининга in vivo
JP6134142B2 (ja) * 2010-02-04 2017-05-24 ギリアド バイオロジクス, インク.Gilead Biologics, Inc. リシルオキシダーゼ様２（ｌｏｘｌ２）に結合する抗体及びその使用方法
US9304134B2 (en) 2010-11-23 2016-04-05 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of anemia
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
US9289467B2 (en) * 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
WO2013086419A1 (en) * 2011-12-09 2013-06-13 California Institute Of Technology Polymer scaffolds and their use in the treatment of vision loss
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
RU2656162C2 (ru) 2012-10-22 2018-05-31 Фоунтейн Биофарма Инк. Антитела к интерлейкину 6 и их применение
RU2015119547A (ru) * 2012-10-25 2016-12-20 МЕДИММЬЮН, ЭлЭлСи Стабильный низковязкий состав с антителом
CN109789224A (zh) * 2016-05-05 2019-05-21 宾夕法尼亚大学理事会 靶向il-6和cd126的dna单克隆抗体
CN106413047A (zh) * 2016-10-31 2017-02-15 北京小米移动软件有限公司 智能设备接入无线网络的方法和装置
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
JP7630906B2 (ja) 2017-02-01 2025-02-18 イェール・ユニヴァーシティー 利尿薬耐性の治療
JP6950242B2 (ja) * 2017-03-31 2021-10-13 ブラザー工業株式会社 通信装置
MA51584A (fr) 2018-01-05 2020-11-11 Corvidia Therapeutics Inc Méthodes de traitement d'une inflammation médiée par il-6 sans immunosuppression
CA3097007A1 (en) 2018-04-20 2019-10-24 Lyvgen Biopharma Co., Ltd. Anti-cd40 antibodies and uses thereof
KR20210070317A (ko) 2018-09-28 2021-06-14 리브젠 바이오파마 코., 엘티디. 조작된 Fc 도메인을 갖는 항-CD40 결합 분자 및 그의 치료적 용도
EP4048701A4 (en) * 2019-10-23 2024-05-29 Lyvgen Biopharma Holdings Limited ANTI-CD40-BINDING MOLECULES AND BISPECIFIC ANTIBODIES CONTAINING THEM
KR20240028975A (ko) * 2021-04-08 2024-03-05 사나 바이오테크놀로지, 인크. Cd8-특이적 항체 구조체들 및 이의 조성물

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
IL88375A (en) * 1988-11-14 1995-07-31 Yeda Res & Dev Monoclonal antibodies that specifically bind interferon-bia 2 natural and recombinant and a natural and recombinant interferon-beta 2 purification method and method
CA1341588C (en) * 1988-01-26 2009-01-06 Michel Revel Human ifn-beta2/i1-6, its purification and use
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JP3614183B2 (ja) * 1993-05-31 2005-01-26 中外製薬株式会社 ヒトインターロイキン−６に対する再構成ヒト抗体
AU6808194A (en) * 1993-05-31 1994-12-20 Chugai Seiyaku Kabushiki Kaisha Reconstructed human antibody against human interleukin-6
FR2707882B1 (fr) * 1993-07-23 1997-08-01 Immunotech Sa Nouveaux kits thérapeutiques anti-médiateurs protéiques, procédé de préparation et compositions pharmaceutiques les renfermant.
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
JPH10324639A (ja) * 1997-03-21 1998-12-08 Chugai Pharmaceut Co Ltd Ｉｌ−６アンタゴニストを有効成分として含有する感作ｔ細胞関与疾患の予防・治療剤
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
RU2318829C2 (ru) 2001-11-14 2008-03-10 Сентокор, Инк. Антитела против il-6, композиции, способы и применение
CA2496523A1 (en) * 2002-08-30 2004-03-11 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human antihuman interleukin-6 antibody and fragment of the antibody
AU2003285578B2 (en) 2002-12-03 2010-07-15 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
DK1644412T4 (en) 2003-07-01 2018-11-12 Ucb Biopharma Sprl MODIFIED ANTIBODY-FAB FRAGMENTS
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
PE20061324A1 (es) 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
SI1960430T1 (sl) 2005-12-09 2015-01-30 Ucb Pharma, S.A. Molekule protiteles s specifiäśnostjo za äśloveĺ ki il-6

Also Published As

Publication number Publication date
US20160039929A1 (en) 2016-02-11
HK1125113A1 (en) 2009-07-31
US20120183996A1 (en) 2012-07-19
SI1960430T1 (sl) 2015-01-30
NZ569234A (en) 2011-07-29
PE20070998A1 (es) 2007-10-09
TWI390035B (zh) 2013-03-21
CA2632628A1 (en) 2007-06-14
BRPI0619595B8 (pt) 2022-12-13
RS53708B1 (en) 2015-04-30
EP1960430B1 (en) 2014-09-24
NO20083066L (no) 2008-09-08
KR101422523B1 (ko) 2014-07-24
US8075889B2 (en) 2011-12-13
AU2006323490B2 (en) 2012-05-24
US20140024077A1 (en) 2014-01-23
HRP20141214T1 (hr) 2015-02-13
IL242434B (en) 2018-04-30
EA200801427A1 (ru) 2008-12-30
EP2336181A1 (en) 2011-06-22
AU2006323490A1 (en) 2007-06-14
KR20130100386A (ko) 2013-09-10
NO344847B1 (no) 2020-05-25
US20070154481A1 (en) 2007-07-05
BRPI0619595A2 (pt) 2011-10-04
PT1960430E (pt) 2015-01-05
AR057224A1 (es) 2007-11-21
ES2525325T3 (es) 2014-12-22
IL191600A (en) 2015-11-30
CN101356194A (zh) 2009-01-28
CA2632628C (en) 2016-01-19
PL1960430T3 (pl) 2015-03-31
KR20080077271A (ko) 2008-08-21
KR101413451B1 (ko) 2014-07-10
EP1960430A1 (en) 2008-08-27
BRPI0619595A8 (pt) 2019-01-15
US9631015B2 (en) 2017-04-25
JP5183484B2 (ja) 2013-04-17
JP2009518023A (ja) 2009-05-07
UA96141C2 (ru) 2011-10-10
US9096668B2 (en) 2015-08-04
TW200728466A (en) 2007-08-01
US20170182159A1 (en) 2017-06-29
BRPI0619595B1 (pt) 2020-09-15
DK1960430T3 (da) 2015-01-05
EP2314626A1 (en) 2011-04-27
ZA200804594B (en) 2010-08-25
EA018044B1 (ru) 2013-05-30
US8486662B2 (en) 2013-07-16
MY147217A (en) 2012-11-14
IL191600A0 (en) 2008-12-29
WO2007066082A1 (en) 2007-06-14
CN101356194B (zh) 2013-06-12

Similar Documents

Publication Publication Date Title
ECSP088613A (es) Moléculas de anticuerpo que tienen especificidad para la il-6 humana
AR051484A1 (es) Moleculas de anticuerpo que tienen especificidad para la il - 17 humana
ECSP056014A (es) MOLÉCULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA
AR061538A1 (es) Moleculas de anticuerpo que se unen a la il-17 humana
ECSP14000329A (es) Moléculas que son anticuerpos con especificidad por ox40 humano
UY32489A (es) Moléculas de anticuerpos que tienen especificidad de unión por il-13 humana
CY1121431T1 (el) Μορια αντισωματος που εχουν ειδικοτητα για τον ανθρωπινο οχ40
CY1121672T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
CO6781516A2 (es) Moléculas de anticuerpos que se unen a il-17a y il-17f
ECSP11010840A (es) Anticuerpos anti-il-13 modificados, composiciones, métodos y usos
DOP2012000104A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
GT200600240A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos
AR060130A1 (es) Formulacion de un anticuerpo monoclonal humano anti- igf-1r
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
CO6420355A2 (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
GT201200318A (es) Anticuerpos hacia gdf8 humano
CO6331296A2 (es) Inmunoglobulinas de dominio variable dual y usos de las mismas
UY31904A (es) Anticuerpos contra il-6 y sus usos
CL2022001684A1 (es) Anticuerpo con especificidad de unión para il-13 humana
CY1115868T1 (el) Μορια αντισωματων που εχουν ειδικο χαρακτηρα για το ανθρωπινο il-6